Results 211 to 220 of about 157,671 (305)

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Gray JE, Laktionov K, Kim SW, Kato T, Wang J, Han Z, Mitchell P, Kuyama S, Tan Chun Bing J, Cundom J, Pinto G, Shepherd FA, Poole L, Lai R, Albayaty M, Amin NP, Kobayashi K, Lee CK.   +17 more
europepmc   +1 more source

Variations in Treatment Prescription and Survival Outcomes Between Older and Younger Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Purpose To investigate treatment variations and outcomes between older (≥ 70 years) and younger (< 70 years) patients with mucosal head and neck squamous cell carcinoma (mHNSCC) treated with radiotherapy. Methods A multicenter retrospective review of patients diagnosed from 2010 to 2018 was conducted.
Farhannah Aly, Joseph Descallar, Purnima Sundaresan, Alexis Andrew Miller, Lois Holloway, Shalini Vinod   +5 more
wiley   +1 more source

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, EarlyView.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source

Amivantamab Monotherapy in Chemorefractory <i>RAS</i>/<i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. [PDF]

J Clin Oncol
Oberstein PE, Hecht JR, Raghav K, Pietrantonio F, Arnold D, Moreno V, Van Cutsem E, Malik RA, Hong YS, Lee MA, Yu-Li Su H, Lee J, Chandana S, Cruz-Correa M, Yuan Y, Ahmad A, Lai KM, Hsu HC, Chen EX, Elez E, Lin CC, Lopez C, Prenen H, Roselló-Keränen S, Velez H, Yeh YM, Heinemann V, Eng C, Beom SH, Tejpar S, Chowdhury S, Lyu X, Kamat M, Curtin JC, Patel B, Xie J, Bhattacharya R, Schnepp RW, Yilmaz E, Iwasawa R, Daksh M, Lorenzini P, Thayu M, Baig M, Kim HS, Han SW.   +45 more
europepmc   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva   +21 more
wiley   +1 more source

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry. [PDF]

NPJ Breast Cancer
Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Tretschock LM, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tauber N, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Michel LL, Wallwiener M, Fasching PA, Schneeweiss A, Maurer C.   +52 more
europepmc   +1 more source

Survival by Detection Pathway in Patients With Lung Cancer—A Nationwide Descriptive Epidemiological Study in Japan

International Journal of Cancer, EarlyView.
Lung cancer is detected primarily through screening, incidental findings, or presentation with symptoms. In Japan, the impact of detection pathway on prognosis is poorly understood, limiting evaluation of screening effectiveness. The authors of the present study analyzed Japanese National Cancer Registry data, comparing clinical characteristics and net
Ryo Koto, Atsuki Yamamoto, Ikumi Takashima, Chikako Iwao, Jung‐ho Shin, Yuko Hayashi, Hiroshi Kitagawa, Yoshiharu Horie   +7 more
wiley   +1 more source

Pre-Analytical and Analytical Challenges in Whole-Exome Sequencing of Formalin-Fixed Paraffin-Embedded Breast and Prostate Cancer Tissue: A Real-World Multicenter Study. [PDF]

Diagnostics (Basel)
Rosa ML, Bordignon C, Schuch JB, Baumont AC, Bessel M, Curzel GD, Cadore NA, Varela APM, Dos Santos GT, Andreis TF, Oliveira FH, Vasconcellos VF, Barros LAR, Souza CP, Barra WF, Louzeiro DLC, Notari A, de Menezes JJ, Liedke PER, Bertollo GA, Gongora ABL, Ascenco HG, Kowalski-Neto E, Oppermann CP, Werutsky G, Santos EM, Brandão FS, Freitas R, Nogueira-Rodrigues A, Mancini ALC, Rosa DD, Macedo GS.   +31 more
europepmc   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

Hyperkalemia in Heart Failure Hospitalizations: An Underreported Contributor to Poor Outcomes and Higher Costs in Brazil. [PDF]

Arq Bras Cardiol
Pecoits-Filho R, Rocha PT, Costa MCD, Schwartzmann P, Moura LAZ, Longato M, Segre N, Rego T, Montenegro C, Moraes TP.   +9 more
europepmc   +1 more source